Department of Neuropsychiatry, Okayama Psychiatric Medical Center, Okayama, Japan.
Department of Neuropsychiatry, Yamanashi Prefectural Kita Hospital, Yamanashi, Japan.
PLoS One. 2020 Jun 18;15(6):e0234864. doi: 10.1371/journal.pone.0234864. eCollection 2020.
The purpose of this study was to develop the Glasgow Antipsychotic Side effects Scale for Clozapine Japanese version (GASS-C-J) and examine its reliability to assess clozapine-related side effects. We developed the GASS-C-J using forward and backward translation. Semantic equivalence of the GASS-C-J to the GASS-C was confirmed by the original author. We then administered the GASS-C-J twice to 109 patients on clozapine treatment at two psychiatric hospitals in Japan. We assessed the internal consistency and test-retest reliability of the GASS-C-J using Cronbach's alpha and weighted kappa coefficient, respectively. We also examined if discrepancies in each GASS-C-J item score between the first and second rating were correlated with items of the Brief Evaluation of Psychosis Symptom Domains (BE-PSD). The Cronbach's alpha coefficient of the GASS-C-J at the first and second rating was 0.78 (95% CI: 0.72 to 0.84) and 0.82 (95% CI: 0.76 to 0.88), respectively. The weighted kappa coefficient of individual and total GASS-C-J item scores ranged from 0.45 to 0.88. Some symptom domains were correlated with discrepancies in specific items of the GASS-C-J: psychotic symptoms and nausea/vomiting (rs = 0.27), thirst (rs = 0.31), and appetite/weight gain (rs = 0.27); disorganized thinking and urinary incontinence (rs = 0.26); depression/anxiety and myoclonus (rs = 0.25), hypersalivation (rs = -0.27), and blurred vision (rs = -0.22). These findings demonstrate that the GASS-C-J can be used in clinical and research settings as a reliable scale to assess clozapine-related side effects.
这项研究的目的是开发氯氮平相关副作用的格拉斯哥抗精神病药副作用量表日语版(GASS-C-J),并检验其评估氯氮平相关副作用的可靠性。我们采用正向和反向翻译开发了 GASS-C-J。通过原始作者确认了 GASS-C-J 与 GASS-C 的语义等效性。然后,我们在日本的两家精神病院对 109 名接受氯氮平治疗的患者进行了两次 GASS-C-J 评估。我们使用 Cronbach's alpha 和加权 kappa 系数分别评估 GASS-C-J 的内部一致性和重测信度。我们还检查了第一次和第二次评分之间每个 GASS-C-J 项目评分的差异是否与 Brief Evaluation of Psychosis Symptom Domains(BE-PSD)的项目相关。GASS-C-J 在第一次和第二次评分时的 Cronbach's alpha 系数分别为 0.78(95%CI:0.72 至 0.84)和 0.82(95%CI:0.76 至 0.88)。个体和总 GASS-C-J 项目评分的加权 kappa 系数范围为 0.45 至 0.88。一些症状领域与 GASS-C-J 的特定项目差异相关:精神病症状和恶心/呕吐(rs = 0.27)、口渴(rs = 0.31)和食欲/体重增加(rs = 0.27);思维紊乱和尿失禁(rs = 0.26);抑郁/焦虑和肌阵挛(rs = 0.25)、流涎过多(rs = -0.27)和视力模糊(rs = -0.22)。这些发现表明,GASS-C-J 可在临床和研究环境中用作评估氯氮平相关副作用的可靠量表。